146 related articles for article (PubMed ID: 8286012)
1. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines.
Naylor MA; Stephens MA; Nolan J; Sutton B; Tocher JH; Fielden EM; Adams GE; Stratford IJ
Anticancer Drug Des; 1993 Dec; 8(6):439-61. PubMed ID: 8286012
[TBL] [Abstract][Full Text] [Related]
2. Novel N-oxides as bioreductive drugs.
Naylor MA
Oncol Res; 1994; 6(10-11):483-91. PubMed ID: 7620216
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
5. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
6. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs.
Gali-Muhtasib HU; Haddadin MJ; Rahhal DN; Younes IH
Oncol Rep; 2001; 8(3):679-84. PubMed ID: 11295102
[TBL] [Abstract][Full Text] [Related]
7. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH; Wilson WR; Denny WA
Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
[TBL] [Abstract][Full Text] [Related]
8. Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicity.
Naylor MA; Sutton BM; Nolan J; O'Neill P; Fielden EM; Adams GE; Stratford IJ
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):333-7. PubMed ID: 8195029
[TBL] [Abstract][Full Text] [Related]
9. Novel and Selective TLR7 Antagonists among the Imidazo[1,2-
Bou Karroum N; Moarbess G; Guichou JF; Bonnet PA; Patinote C; Bouharoun-Tayoun H; Chamat S; Cuq P; Diab-Assaf M; Kassab I; Deleuze-Masquefa C
J Med Chem; 2019 Aug; 62(15):7015-7031. PubMed ID: 31283223
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
[TBL] [Abstract][Full Text] [Related]
11. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
[TBL] [Abstract][Full Text] [Related]
12. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents.
Ortega MA; Morancho MJ; Martínez-Crespo FJ; Sainz Y; Montoya ME; López de Ceráin A; Monge A
Eur J Med Chem; 2000 Jan; 35(1):21-30. PubMed ID: 10733600
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and cytotoxicity of 2-methyl-4, 9-dihydro-1-substituted-1H-imidazo[4,5-g]quinoxaline-4,9-diones and 2,3-disubstituted-5,10-pyrazino[2,3-g]quinoxalinediones.
Yoo HW; Suh ME; Park SW
J Med Chem; 1998 Nov; 41(24):4716-22. PubMed ID: 9822542
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective anti-tumor agents.
Hu Y; Xia Q; Shangguan S; Liu X; Hu Y; Sheng R
Molecules; 2012 Aug; 17(8):9683-96. PubMed ID: 22890172
[TBL] [Abstract][Full Text] [Related]
16. Fused pyrazine mono-n-oxides as bioreductive drugs. II Cytotoxicity in human cells and oncogenicity in a rodent transformation assay.
Langmuir VK; Laderoute KR; Mendonca HL; Sutherland RM; Hei TK; Liu SX; Hall EJ; Naylor MA; Adams GE
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):79-84. PubMed ID: 12118568
[TBL] [Abstract][Full Text] [Related]
17. 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
Ohmori J; Shimizu-Sasamata M; Okada M; Sakamoto S
J Med Chem; 1997 Jun; 40(13):2053-63. PubMed ID: 9207947
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
[TBL] [Abstract][Full Text] [Related]
19. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
[TBL] [Abstract][Full Text] [Related]
20. Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents.
Diab-Assef M; Haddadin MJ; Yared P; Assaad C; Gali-Muhtasib HU
Mol Carcinog; 2002 Apr; 33(4):198-205. PubMed ID: 11933073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
